» Articles » PMID: 26598234

MiR-223 Deficiency Protects Against Fas-Induced Hepatocyte Apoptosis and Liver Injury Through Targeting Insulin-Like Growth Factor 1 Receptor

Overview
Journal Am J Pathol
Publisher Elsevier
Specialty Pathology
Date 2015 Nov 25
PMID 26598234
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

The biological functions and molecular mechanisms of miR-223 action in liver cells and liver diseases remain unclear. We therefore determined the effect and mechanism of action of miR-233 in Fas-induced hepatocyte apoptosis and liver injury. Wild-type (WT) and miR-223 knockout (KO) mice were treated i.p. with 0.5 μg/g body weight anti-Fas antibody Jo2, and the animals were monitored for survival and the extent of liver injury. Although WT mice died 4 to 6 hours after Jo2 injection (n = 6), all of the miR-223 KO mice (n = 6) survived. In comparison to WT mice, the miR-223 KO mice showed resistance to Fas-induced liver injury, as indicated by less tissue damage under histopathological examination, fewer apoptotic hepatocytes under caspase-3 immunostaining, and less elevation of serum transaminases. miR-223 KO livers showed less caspase-3, caspase-8, and caspase-9 activation and less poly (ADP-ribose) polymerase cleavage compared with WT livers (P < 0.05). Furthermore, tail vein injection of miR-223 lentiviral vector to miR-223 KO mice restored Jo2-induced liver injury. Transfection of miR-223 KO hepatocytes with miR-223 mimic enhanced Jo2-induced activation of caspase-3, caspase-8, and caspase-9, whereas transfection of WT hepatocytes with the miR-223 inhibitor attenuated Jo2-induced apoptosis. These findings demonstrate that miR-223 deficiency protects against Fas-induced hepatocyte apoptosis and liver injury. Further in vitro and in vivo data indicate that miR-223 regulates Fas-induced hepatocyte apoptosis and liver injury by targeting the insulin-like growth factor 1 receptor.

Citing Articles

The effect of SNPs in lncRNA as ceRNA on the risk and prognosis of hepatocellular carcinoma.

Mo H, Wang X, Ji G, Liang X, Yang Y, Sun W BMC Genomics. 2022; 23(1):769.

PMID: 36418931 PMC: 9685961. DOI: 10.1186/s12864-022-09010-9.


Hepatic gene expression and functional changes associated with nonalcoholic steatohepatitis.

Matsumoto K, Kato Y, Hayashi M, Miura R, Monzen S, Chiba M Mol Med Rep. 2022; 26(5).

PMID: 36052866 PMC: 9727582. DOI: 10.3892/mmr.2022.12841.


MiR-223 as a Regulator and Therapeutic Target in Liver Diseases.

Gu J, Xu H, Chen Y, Li N, Hou X Front Immunol. 2022; 13:860661.

PMID: 35371024 PMC: 8965842. DOI: 10.3389/fimmu.2022.860661.


Anti-Inflammatory Effect of Muscle-Derived Interleukin-6 and Its Involvement in Lipid Metabolism.

Nara H, Watanabe R Int J Mol Sci. 2021; 22(18).

PMID: 34576053 PMC: 8471880. DOI: 10.3390/ijms22189889.


MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease.

Fang Z, Dou G, Wang L Int J Biol Sci. 2021; 17(7):1851-1863.

PMID: 33994867 PMC: 8120467. DOI: 10.7150/ijbs.59588.


References
1.
Peter M, Budd R, Desbarats J, Hedrick S, Hueber A, Newell M . The CD95 receptor: apoptosis revisited. Cell. 2007; 129(3):447-50. DOI: 10.1016/j.cell.2007.04.031. View

2.
Strasser A, Jost P, Nagata S . The many roles of FAS receptor signaling in the immune system. Immunity. 2009; 30(2):180-92. PMC: 2956119. DOI: 10.1016/j.immuni.2009.01.001. View

3.
Caro J, Poulos J, Ittoop O, Pories W, Flickinger E, Sinha M . Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver. J Clin Invest. 1988; 81(4):976-81. PMC: 329620. DOI: 10.1172/JCI113451. View

4.
Fazi F, Rosa A, Fatica A, Gelmetti V, De Marchis M, Nervi C . A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell. 2005; 123(5):819-31. DOI: 10.1016/j.cell.2005.09.023. View

5.
Giordano S, Columbano A . MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma?. Hepatology. 2012; 57(2):840-7. DOI: 10.1002/hep.26095. View